All In Biotech

Drug Trial Radar · NCT01357603

Comparative Glucose Clamp Study of Wockhardt's Recombinant Insulin Analog Glargine(Glaritus) With Lantus in T1DM

A Randomized, Double-blind, Two Period, Cross Over Glucose Clamp Study to Test for Bioeqivalence Between Two Long Acting Insulin Analogs-Wockhardt's Glaritus™ (Insulin Glargine) and Lantus (Insulin Glargine) in Subjects With Type 1 Diabetes

Last checked: Nov 20, 2026Latest source record: Jan 25, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 111 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

111

Actual

Start

Jun 2011

Primary completion

May 2012

Study completion Aug 2012

Sponsor

Lead sponsor
WockhardtIndustry
Sponsor type
Industry
First posted
May 20, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Health services research
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this trial is to demonstrate bioequivalence of Glaritus® to Lantus® with regard to its total and to its maximum serum insulin concentrations.

Conditions

  • Type1 Diabetes

Interventions

  • GlargineBiological

    dosage form: Subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Bioequivalence based on Pharmacokinetic parameter:AUC INS-GLR 0-24h.Time frame: over 24hrs post dose
  2. Bioequivalence based on Pharmacodynamic parameter: AUC GIR 0-24hrsTime frame: over 24hrs post dose
  3. Pharmacokinetic Parameters: Maximum concentration (Cmax)Time frame: over 24hrs post dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Profil Institute for clinical Research

    Chula Vista, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.